Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessing assumptions for statistical analyses in randomised clinical trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Network meta-analysis: the highest level of medical evidence?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Redefining the 'E' in EBM

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Acupuncture for chronic hepatitis B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

A Cochrane systematic review on immediate-release methylphenidate for adults with attention deficit hyperactivity disorder (ADHD) was withdrawn from the Cochrane Library on 26 May 2016 after substantial criticism of its methods and flawed conclusions. Retraction of scientific papers on this basis is unusual but can be necessary. We provide a summary of the criticism that led to the withdrawal. We detail the methodological flaws of the withdrawn Cochrane systematic review and general issues of bias and shortcomings of the included ADHD trials: cross-over designs compared with parallel-group designs, exclusion of participants with psychiatric comorbidity, absence of 'functional outcomes' and use of clinical outcomes with limited relevance, short trial duration and small trial populations, broken blinding caused by easily recognisable side effects, combining outcome assessments by trial investigators and participants, outcome reporting bias, poor evaluation of cardiovascular and psychiatric harms and conflicts of interest of trialists and systematic reviewers. The withdrawal of the Cochrane systematic review signals recognition of previous unreliable clinical ADHD research. We conclude that clinical trials of immediate-release methylphenidate in adults with ADHD are of very low quality. We urgently need well-conducted long-term trials free of bias to assess the benefits and harms of central stimulant treatment in adult ADHD.

OriginalsprogEngelsk
TidsskriftEvidence-Based Medicine
Vol/bind22
Udgave nummer4
Sider (fra-til)143-147
ISSN1356-5524
DOI
StatusUdgivet - 2017

ID: 51438932